Assenagon Asset Management S.A. Takes $437,000 Position in Enovis Co. (NYSE:ENOV)

Assenagon Asset Management S.A. bought a new position in Enovis Co. (NYSE:ENOV - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 9,969 shares of the company's stock, valued at approximately $437,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ENOV. Confluence Investment Management LLC purchased a new position in shares of Enovis in the fourth quarter valued at $3,494,000. Sei Investments Co. grew its stake in shares of Enovis by 50.9% in the 2nd quarter. Sei Investments Co. now owns 223,358 shares of the company's stock worth $10,096,000 after buying an additional 75,317 shares in the last quarter. Chartwell Investment Partners LLC increased its holdings in shares of Enovis by 25.6% in the 3rd quarter. Chartwell Investment Partners LLC now owns 201,652 shares of the company's stock worth $8,681,000 after buying an additional 41,089 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Enovis by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 921,437 shares of the company's stock valued at $39,678,000 after buying an additional 80,165 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Enovis in the 3rd quarter valued at about $1,050,000. Institutional investors own 98.45% of the company's stock.

Enovis Stock Up 1.1 %

ENOV stock traded up $0.51 during trading on Friday, hitting $47.78. The company had a trading volume of 744,387 shares, compared to its average volume of 1,123,152. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. Enovis Co. has a 52-week low of $38.27 and a 52-week high of $65.03. The company has a 50 day simple moving average of $45.93 and a 200-day simple moving average of $44.46.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.11. The firm had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Enovis's quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.56 earnings per share. As a group, research analysts predict that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on ENOV. JMP Securities began coverage on Enovis in a research report on Thursday, October 3rd. They set an "outperform" rating and a $62.00 price objective on the stock. Needham & Company LLC restated a "buy" rating and issued a $65.00 price target on shares of Enovis in a research report on Thursday, November 7th. Finally, Evercore ISI dropped their price objective on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating for the company in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $65.86.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.